R. Berger
University of Minnesota
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by R. Berger.
Cancer Genetics and Cytogenetics | 1989
Diane C. Arthur; R. Berger; Harvey M. Golomb; G.J. Swansbury; B.R. Reeves; Giuliana Alimena; H. Van den Berghe; Clara D. Bloomfield; A. de la Chapelle; Gordon W. Dewald; O.M. Garson; A. Hagemeijer; Yasuhiko Kaneko; F. Mitelman; R.V. Pierre; Tapani Ruutu; M. Sakurai; S.D. Lawler; Jd Rowley
To evaluate further the prognostic significance of karyotype at diagnosis of acute myelogenous leukemia (AML), we have made a follow-up study of 711 patients who were diagnosed between January 1, 1980, and March 31, 1982, and who were originally reported by the Fourth International Workshop on Chromosomes in Leukemia (4IWCL). Three different chromosomal classifications were evaluated, including presence of normal and abnormal metaphases (NN-AN-AA classification), a modification of the Chicago classification, and a complexity classification. All three chromosomal classifications were shown to correlate significantly with outcome in patients with de novo AML. Furthermore, the NN-AN-AA classification and the complexity classification had independent prognostic significance when age, sex, and FAB morphology were also considered in multivariate analyses of survival. These data provide further evidence that karyotype is an important factor in predicting the outcome of patients with AML.
Cancer Genetics and Cytogenetics | 1994
G.J. Swansbury; S.D. Lawler; Giuliana Alimena; Diane C. Arthur; R. Berger; H. Van den Berghe; Clara D. Bloomfield; A. de la Chappelle; Gordon W. Dewald; O.M. Garson; A. Hagemeijer; F. Mitelman; Janet D. Rowley; M. Sakurai
Patients with acute myeloid leukemia (AML, equivalent to acute non-lymphoblastic leukemia [ANLL]) who were studied at the Fourth and Sixth International Workshops on Chromosomes in Leukemia and who have long survival have been re-assessed to identify factors which may be associated with good prognosis in AML. In a long-term survivor (LTS) group, there were more cases than expected in each age decade below 50, more cases than expected with FAB type M3, and fewer cases than expected of secondary leukemia. Of the distribution of chromosome abnormalities, t(15;17), t(8;21), and inv/del(16) were over-represented, and -5, -7, and rearrangements of 11q were under-represented. Multivariate analysis of all patients showed that age group, cytogenetic classification, FAB type, and sex all had independent, significant effects on survival. A new observation from a very small subgroup of patients was that deletion of 7q without concurrent abnormality of chromosome 5 appeared to be associated with a good prognosis.
Cancer Genetics and Cytogenetics | 1989
O.M. Garson; A. Hagemeijer; M. Sakurai; B.R. Reeves; G.J. Swansbury; G.J. Williams; Giuliana Alimena; Diane C. Arthur; R. Berger; A. de la Chapelle; Gordon W. Dewald; F. Mitelman; H. Van den Berghe; S.D. Lawler; Jd Rowley
In order to investigate the cytogenetic patterns in relapsed acute myelogenous leukemia (AML), a clinical and cytogenetic follow-up of patients newly diagnosed for the Fourth International Workshop on Chromosomes in Leukemia (4IWCL) was evaluated at the 6IWCL. Information was received on 103 patients in relapse who were then classified into seven groups according to the diagnostic karyotype. These groups were: normal, t(8;21), t(15;17), +8, a single specific abnormality either numerical or structural other than those already listed, a single nonrandom or miscellaneous abnormality again either numerical or structural, and complex abnormalities. The patients age, diagnostic FAB type, the number of relapses, the total survival time, and the karyotype in relapse were considered in each of these cytogenetic groups. The remission and survival rates were comparable in all groups except the +8 group, where patients relapsed earlier and had a shorter survival time. Multiple relapses occurred most frequently in the t(8;21) group, whereas none of the patients with t(15;17) relapsed more than once, although the total survival time was similar to the two groups. Thirty-nine percent of the patients relapsed with the same karyotype as at diagnosis. A more complex karyotype showing evolution was found in 53%, and 8% showed either a less-complicated karyotype or appeared to have reverted to normal. Numerical abnormalities in relapse frequently involved trisomy of chromosomes 8 and/or 21. There was a nonrandom development of 9q- with relapse in patients with t(8;21). A pericentric inversion of chromosome 4, and abnormality infrequently reported at diagnosis, was found in relapse in association with t(15;17), t(8;21), and +8 karyotypes. Changes considered to be typically secondary in nature involving 5q, 7q, and 12p were seen in only seven cases. Twenty-one patients who had an apparently normal karyotype at diagnosis remained normal in relapse, indicating that absence of clonal chromosome abnormality is a real observation in AML rather than a failure of detection.
Blood | 1986
Clara D. Bloomfield; Anne I. Goldman; G Alimena; R. Berger; Gh Borgstrom; L Brandt; D. Catovsky; A de la Chapelle; Gordon W. Dewald; O.M. Garson
Cytogenetic and Genome Research | 1982
R. Berger; A. Bernheim; A. de la Chapelle
Cytogenetic and Genome Research | 1984
L.A. Menlove; Elizabeth B. Robson; L.U. Lamm; J.L. Hamerton; S. Povey; N.E. Morton; D. Bootsma; Kenneth K. Kidd; T.B. Shows; P.J. McAlpine; R.L. Miller; C.W. Partridge; Frank H. Ruddle; P.S. Gerald; Karl-Heinz Grzeschik; M.A. Ferguson-Smith; D. R. Cox; A. Westerveld; Susan L. Naylor; Orlando J. Miller; D. Drayna; Paul J. Goodfellow; V.A. McKusick; P.M. Conneally; A. de la Chapelle; R. Berger; T.H. Roderick; P.A. Lalley; M.T. Davisson; S.J. O’Brien
Cytogenetic and Genome Research | 1984
L.A. Menlove; Elizabeth B. Robson; L.U. Lamm; J.L. Hamerton; S. Povey; N.E. Morton; D. Bootsma; Kenneth K. Kidd; T.B. Shows; P.J. McAlpine; R.L. Miller; C.W. Partridge; Frank H. Ruddle; P.S. Gerald; Karl-Heinz Grzeschik; M.A. Ferguson-Smith; D. R. Cox; A. Westerveld; Susan L. Naylor; Orlando J. Miller; D. Drayna; Paul J. Goodfellow; V.A. McKusick; P.M. Conneally; A. de la Chapelle; R. Berger; T.H. Roderick; P.A. Lalley; M.T. Davisson; S.J. O’Brien
Cytogenetic and Genome Research | 1984
L.A. Menlove; Elizabeth B. Robson; L.U. Lamm; J.L. Hamerton; S. Povey; N.E. Morton; D. Bootsma; Kenneth K. Kidd; T.B. Shows; P.J. McAlpine; R.L. Miller; C.W. Partridge; Frank H. Ruddle; P.S. Gerald; Karl-Heinz Grzeschik; M.A. Ferguson-Smith; D. R. Cox; A. Westerveld; Susan L. Naylor; Orlando J. Miller; D. Drayna; Paul J. Goodfellow; V.A. McKusick; P.M. Conneally; A. de la Chapelle; R. Berger; T.H. Roderick; P.A. Lalley; M.T. Davisson; S.J. O’Brien
Cytogenetic and Genome Research | 1982
L.A. Menlove; Elizabeth B. Robson; L.U. Lamm; J.L. Hamerton; S. Povey; N.E. Morton; D. Bootsma; Kenneth K. Kidd; T.B. Shows; P.J. McAlpine; R.L. Miller; C.W. Partridge; Frank H. Ruddle; P.S. Gerald; Karl-Heinz Grzeschik; M.A. Ferguson-Smith; D. R. Cox; A. Westerveld; Susan L. Naylor; Orlando J. Miller; D. Drayna; Paul J. Goodfellow; V.A. McKusick; P.M. Conneally; A. de la Chapelle; R. Berger; T.H. Roderick; P.A. Lalley; M.T. Davisson; S.J. O’Brien
Cytogenetic and Genome Research | 1985
H.F. Willard; M.H. Skolnick; P.L. Pearson; Jean-Louis Mandel; P.M. Conneally; J.H. Edwards; Kenneth K. Kidd; Jean Marc Lalouel; N.E. Morton; Jurg Ott; Ray White; P. Tippett; Jean-Claude Kaplan; M. Smith; M.A. Spence; A. de la Chapelle; P.J. McAlpine; T.B. Shows; R.L. Miller; A.J. Pakstis; James F. Gusella; L.U. Lamm; B. Olaisen; Karl-Heinz Grzeschik; H.H. Kazazian; D. R. Cox; T. Gedde-Dahl; Susan L. Naylor; D.J. Shaw; P.N. Goodfellow
Collaboration
Dive into the R. Berger's collaboration.
University of Texas Health Science Center at San Antonio
View shared research outputs